EU Guidelines on Good Distribution Practice of Active Substances for Medicinal Products for Human Use
The EU guidelines of 19 March 2015 on good distribution practice of active substances for human medicinal products (2015/C 95/01). They extend GDP upstream of the finished product: importers and distributors of active substances must register with their competent authority and operate a quality system covering personnel, documentation, orders, receipt, storage, deliveries, returns, complaints, recalls, and self-inspection — closing the gap between ICH Q7 manufacturing GMP and finished-product GDP.
What this does not cover
stated in the document's own scope- Covers procurement, holding, and supply of active substances; manufacturing steps — including repackaging and relabelling — are manufacturing under ICH Q7 / EU GMP Part II, not distribution.
- Applies to active substances for human medicinal products; the veterinary regime is Implementing Regulation (EU) 2021/1280.
- Governs the distribution of APIs, not of finished medicinal products, which follow the 2013 GDP guidelines.
- Sets GDP expectations; the registration obligation itself comes from Article 52a of Directive 2001/83/EC.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The guidelines of 19 March 2015 (2015/C 95/01) apply good distribution practice to active substances — the APIs from which human medicines are made — rather than to finished products. They require importers and distributors of active substances to operate a documented quality system and set out expectations for personnel, documentation, orders, receipt, storage, deliveries to customers, returns, complaints, recalls, and self-inspection. Their purpose is supply-chain integrity upstream of the finished medicine: an active substance must remain traceable, stored under the right conditions, and protected from substitution or contamination between the API manufacturer and the medicine manufacturer that uses it.
Scope & applicability
Importers and distributors of active substances for human medicinal products in the EU, registered under Article 52a of Directive 2001/83/EC. Manufacture of active substances remains governed by ICH Q7 / EU GMP Part II; finished-product distribution by the 2013 GDP guidelines.
Legal basis & how it acquires force
Guidelines adopted by the European Commission under Article 47 of Directive 2001/83/EC, as amended by the Falsified Medicines Directive (2011/62/EU). The same amending directive inserted Article 52a, which obliges importers and distributors of active substances to register with the competent authority of their Member State — the registration these guidelines give technical content to. They are Commission guidance interpreting binding obligations, published in the Official Journal as 2015/C 95/01 and applicable since 2015.
Document structure
| Part | Covers |
|---|---|
| Scope | The distribution activities covered, and the boundary with manufacturing activities governed by GMP |
| Quality system and personnel | The documented quality system, responsibilities, and training for staff involved in distribution |
| Documentation | Procedures, instructions, and records providing traceability of each supply |
| Operations | Orders, receipt, storage, deliveries to customers, and verification of supplier and customer legitimacy |
| Returns, complaints and recalls | Handling returned active substances, quality complaints, and recall execution |
| Self-inspections | Periodic internal audit of the distribution operation against the guidelines |
Key requirements
- Register as an importer or distributor of active substances with the competent authority
- Operate a documented quality system appropriate to the distribution activities performed
- Maintain traceability: records identifying each supply of an active substance through the chain
- Store and transport active substances under the conditions their documentation requires
- Handle returns, complaints, and recalls, and verify supplier and customer bona fides
- Perform self-inspections of the GDP operation
Implementation tips
- Repackaging or relabelling an active substance is manufacturing, not distribution — it needs ICH Q7-level GMP controls, not just this guideline
Revision notes
Published 19 March 2015 under the Falsified Medicines Directive amendments to Directive 2001/83/EC; the veterinary counterpart arrived as Implementing Regulation (EU) 2021/1280.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The guidelines complete the EU's chain of custody for medicines: ICH Q7 / EU GMP Part II govern how an active substance is made, these guidelines govern how it is distributed, and the 2013 GDP guidelines (2013/C 343/01) govern the finished product's distribution. The veterinary counterpart is Commission Implementing Regulation (EU) 2021/1280, which turned closely similar technical content into directly binding law under Regulation (EU) 2019/6.
2015/C 95/01: frequently asked questions
Quick answers to common questions about 2015/C 95/01.
Who must follow the EU GDP guidelines for active substances?
Importers and distributors of active substances for human medicinal products operating in the EU. They must register with their Member State's competent authority under Article 52a of Directive 2001/83/EC and operate the quality system and controls the 2015 guidelines describe.
Is repackaging an active substance a distribution activity?
No. Repackaging and relabelling are manufacturing operations. They fall under the GMP for active substances (ICH Q7 / EU GMP Part II), because opening the original container creates contamination and mix-up risks that distribution controls alone cannot manage.
How do these guidelines relate to the 2013 EU GDP guidelines?
They are siblings under the same directive. The 2013 guidelines (2013/C 343/01) cover distribution of finished medicinal products; the 2015 guidelines (2015/C 95/01) extend equivalent principles upstream to active substances. A wholesaler handling both needs to meet both texts.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.